Organovo Appoints New Board Member

World News: . []

SAN DIEGO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that its board of directors has appointed one new member.  David Shapiro, M.D., Chief Medical Officer of Intercept Pharmaceuticals, Inc. (“Intercept”), will join Organovo’s board, effective immediately.  Dr. Shapiro’s appointment increases the number of Organovo directors to eight.

“David brings significant liver-focused clinical development and medical expertise to our board,” said Taylor J. Crouch, CEO, Organovo.  “His senior leadership experience across the life sciences sector adds to the strength of our already outstanding board, and I’m confident he’ll make a significant contribution as we complete the preclinical studies for our liver therapeutic tissue and move toward our first Investigational New Drug (“IND”) application in calendar 2020.  David has played a key role in establishing his current company as a leader in treating liver disease, including a commercial product addressing primary biliary cholangitis (“PBC”) and a late-stage development program focused on non-alcoholic steatohepatitis (“NASH”).  I’m grateful for his willingness to join the board at such an important time in our organizational development, as well as the ongoing support from all of our directors.”     

Dr. David Shapiro has over 30 years of clinical development experience in the pharmaceutical industry.  He has served as the Chief Medical Officer of Intercept Pharmaceuticals, Inc. since November 2017, having previously served as its Chief Medical Officer and Executive Vice President, Research & Development since 2008.  Dr. Shapiro founded a consulting company, Integrated Quality Resources, that focused on development stage biopharmaceutical companies and was active in this role from 2005 to 2008.  From 2000 to 2005, Dr. Shapiro was Executive Vice President, Medical Affairs and Chief Medical Officer of Idun Pharmaceuticals, Inc., prior to its acquisition by Pfizer Inc.  From 1995 to 1998, he was President of the Scripps Medical Research Center at Scripps Clinic.  He served as Vice President, Clinical Research at Gensia and as Director and Group Leader, Hypertension Clinical Research at Merck Research Laboratories from 1985 to 1990. 

Investor & Press Contact:

Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com

More news and information about Organovo, Inc.

Published By:

Globe Newswire: 13:05 GMT Thursday 6th December 2018

Published: .

Search for other references to "organovo" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us